Related Experiment Video
Updated: Jun 26, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic
Wen-Hsin Chang1, Andrew I Chin2, Ching-Hsien Chen1
1Division of Nephrology, Department of Internal Medicine, University of California, Davis, Davis, CA, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA, USA; Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, USA.
Abstract:
Here, we present a protocol for a preclinical ex vivo platform combining experimental flexibility with preservation of the tumor microenvironment. We outline steps for isolating human peripheral blood mononuclear cells (PBMCs), preparing patient-derived precision-cut tumor slices (PCTSs), cryopreserving the samples, and setting up the co-culture system. We provide instructions for treatment applications, interactions, and analyzing therapy responses. By preserving tumor architecture and heterogeneity, this model is applicable for evaluating tumor characteristics, immune interactions, and treatment efficacy in translational cancer research.
